4109.TWO Jia Jie Biomedical Co Ltd
- Market cap
- TWD 1.20B
- P/E
- 336.7x
- P/B
- 0.77x
- ROE
- -4.2%
- Dividend yield
- 4.95%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4109.TWO undervalued?
Graham numberThe Graham number of Jia Jie Biomedical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jia Jie Biomedical Co Ltd fundamental analysis
No fundamental analysis for Jia Jie Biomedical Co Ltd yet.
Jia Jie Biomedical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jia Jie Biomedical Co Ltd
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules; and import and export, distributi…
Full company profileJia Jie Biomedical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jia Jie Biomedical Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 626M | 522M | 402M | 343M | 270M | 242M | 318M | 333M | 537M | 485M | 536M |
| Gross Profit | 223M | 132M | 110M | 88.0M | 41.7M | 83.8M | 117M | 118M | 173M | 150M | 148M |
| Operating Income | 37.8M | -59.2M | -43.7M | -24.4M | -48.3M | -1.23M | -14.4M | -66.5M | 33.2M | 696K | 4.94M |
| EBITDA | - | -212M | 27.6M | -4.23M | -25.3M | 18.8M | 12.3M | 162M | 242M | 77.7M | -31.1M |
| Net Income | 11.6M | -232M | 2.47M | -24.5M | -31.9M | 5.34M | -5.47M | 144M | 211M | 50.3M | -68.8M |
| EPS | - | -3.37 | 0.04 | -0.40 | -0.36 | 0.06 | -0.06 | 1.58 | 2.08 | 0.42 | -0.58 |
| Balance Sheet | |||||||||||
| Total Assets | 1.65B | 1.32B | 1.12B | 856M | 989M | 1.02B | 1.00B | 1.41B | 1.48B | 1.89B | 1.88B |
| Total Liabilities | 685M | 622M | 404M | 161M | 81.4M | 86.5M | 80.0M | 343M | 123M | 175M | 224M |
| Shareholders' Equity | 935M | 690M | 708M | 695M | 909M | 908M | 898M | 1.05B | 1.33B | 1.68B | 1.62B |
| Cash & Short-term Investments | 155M | 138M | 155M | 104M | 344M | 172M | 126M | 354M | 113M | 296M | 241M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -76.5M | -13.7M | -13.1M | 24.7M | 27.1M | 4.37M | -8.78M | -4.49M | 44.3M | 21.3M | 2.87M |
| Capital Expenditure | 32.1M | 3.49M | 8.34M | 3.05M | 1.63M | 1.52M | 17.9M | 8.61M | 19.6M | 85.5M | 17.7M |
| Free Cash Flow | - | -1.46M | -5.66M | 21.7M | 25.5M | 2.85M | -26.6M | -13.1M | 24.7M | -64.2M | -14.8M |
| Ratios | |||||||||||
| ROE | 1.2% | -33.6% | 0.3% | -3.5% | -3.5% | 0.6% | -0.6% | 13.8% | 15.9% | 3.0% | -4.2% |
| ROA | 0.7% | -17.6% | 0.2% | -2.9% | -3.2% | 0.5% | -0.5% | 10.2% | 14.3% | 2.7% | -3.7% |
| Net Profit Margin | 1.9% | -44.5% | 0.6% | -7.1% | -11.8% | 2.2% | -1.7% | 43.3% | 39.4% | 10.4% | -12.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jia Jie Biomedical Co Ltd dividends
- Dividend yield
- 4.95%
- Forward dividend
- 0.20 TWD
- Payout ratio
- 118.1%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 59.4M | 0.50 | 118.1% |
| 2024 | TWD 49.4M | 0.49 | 23.4% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | TWD 6.25M | 0.09 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 848.7829:1000 on Mar 21, 2019.
Who owns Jia Jie Biomedical Co Ltd
- Insiders 51.88%
- Institutions 0.00%
- Public & others 48.13%
- Shares outstanding 119M
- Free float 97.9M
Jia Jie Biomedical Co Ltd company profile
- Company name
- Jia Jie Biomedical Co Ltd
- Ticker
- 4109.TWO
- ISIN
- TW0004109004
- Exchange
- Taiwan OTC Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Fiscal year end
- December
- Address
- No. 61, Jiuru 1st Road, Kaohsiung, Taiwan, 807
- Phone
- 886 7 976 1598
- Website
- jiajiebio.com
About Jia Jie Biomedical Co Ltd
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules; and import and export, distribution, bidding, quotation of the products. It also involved in the wholesale of nonalcoholic beverages, candy, baked food, supplementary food, groceries, daily commodities, and cosmetics; production of water purification equipment and related parts; life and property insurance brokerage business; development and production of aquatic product technology; and development of biological products. The company was formerly known as Murad Chia Jei Biotechnology Co., Ltd. and changed its name to Jia Jie Biomedical Co., Ltd. in June 2019. Jia Jie Biomedical Co., Ltd. was founded in 1995 and is based in Kaohsiung, Taiwan.
Jia Jie Biomedical Co Ltd management
3- Wen-Fang HsiehChief Executive Officer
- Ming-Chuan TsengPresident
- Qinghong LinVP of Finance Department & Accounting supervisor